STOCKWATCH
·
Biotechnology: Biological Products (No Diagnostic Substances)
Corporate ActionMay 7, 2026, 05:21 PM

Alector Establishes $125M At-The-Market Equity Offering

AI Summary

Alector, Inc. has entered into a Sales Agreement with TD Securities (USA) LLC to establish an at-the-market equity offering program. Under this agreement, Alector may sell up to $125,000,000 of its common stock from time to time. The net proceeds from any sales are intended for general corporate purposes, including research, development, manufacturing of product candidates, working capital, and potential strategic transactions.

Key Highlights

  • Alector entered a Sales Agreement with TD Securities (USA) LLC for an at-the-market equity offering.
  • The company may offer and sell up to $125,000,000 of its common stock.
  • Sales will be made through "at-the-market" offerings or negotiated transactions.
  • Proceeds are for general corporate purposes, including R&D, working capital, and potential acquisitions.
  • TD Cowen will receive compensation of up to 3.0% of the gross sales price.
ALEC
Biotechnology: Biological Products (No Diagnostic Substances)
Alector, Inc.

Price Impact